At Aptose Biosciences, we are building a pipeline of novel and targeted oncology therapies with the potential to serve specific populations of cancer patients.
Our pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of conventional anti-cancer therapies through simultaneous targeting of key drivers of disease in cancer cells without overlapping toxicities and thus preserving the quality of life in cancer patients.
View PipelineWe have two clinical-stage investigational products for hematologic malignancies.
Aptose Biosciences has two clinical-stage investigational products for hematologic malignancies: tuspetinib, an oral, potent myeloid kinase inhibitor, and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor.
View Clinical TrialsA Phase 1/2 Study of Tuspetinib (HM43239) in AML
View Clinical TrialsLuxeptinib (CG-806), an oral, mutation-agnostic FLT3/BTK inhibitor, is in a Phase 1a/b study in patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL).
View Clinical TrialsLuxeptinib (CG-806), an oral, mutation-agnostic FLT3/BTK inhibitor, is in a Phase 1a/b study in patients with relapsed or refractory acute myeloid leukemia (AML).
View Clinical Trials
Our leadership team is comprised of distinguished individuals who possess an actionable blend of academic and industry experience, having served in numerous leadership roles throughout their careers.